Why United Therapeutics Corporation (UTHR) Stock Rose 12.5% on Sep 30, 2026
What happened
United Therapeutics surged +14.51% to $551.32 after a federal court ruled unfavorably against competitor Liquidia Corp in a patent dispute over the rival pulmonary hypertension drug Yutrepia, reducing competitive pressure on UTHR's Tyvaso franchise (web_catalyst via Google AI Overview). Volume reached 1.85M shares, 4.87x the time-adjusted average, signaling strong conviction behind the move.
UTHR earnings on 2026-11-04 (consensus EPS $6.46); monitor Liquidia's next steps in the patent dispute and any appeals.
Other developments that session
United Therapeutics Corporation (UTHR) filed a new 8-K on September 8, 2026. The filing does not disclose what event or information triggered it.
Analyst maintains Buy rating at $535/share valuation despite Tyvaso revenue declines from Yutrepia competition.
Federal judge ruled Liquidia's lung drug infringes United Therapeutics' patent, validating UTHR's IP protection.
Frequently asked questions
Why did United Therapeutics Corporation (UTHR) stock rise on Sep 30, 2026?
United Therapeutics surged +14.51% to $551.32 after a federal court ruled unfavorably against competitor Liquidia Corp in a patent dispute over the rival pulmonary hypertension drug Yutrepia, reducing competitive pressure on UTHR's Tyvaso franchise (web_catalyst via Google AI Overview). Volume reached 1.85M shares, 4.87x the time-adjusted average, signaling strong conviction behind the move.
How much did UTHR stock rise on Sep 30, 2026?
UTHR rose 12.5% during the Sep 30, 2026 trading session.